NO941142L - Tumor-nekrosefaktormuteiner - Google Patents

Tumor-nekrosefaktormuteiner

Info

Publication number
NO941142L
NO941142L NO941142A NO941142A NO941142L NO 941142 L NO941142 L NO 941142L NO 941142 A NO941142 A NO 941142A NO 941142 A NO941142 A NO 941142A NO 941142 L NO941142 L NO 941142L
Authority
NO
Norway
Prior art keywords
human
tnf
receptor
muteins
wild
Prior art date
Application number
NO941142A
Other languages
English (en)
Other versions
NO941142D0 (no
Inventor
David Banner
Werner Lesslauer
Hansruedi Lotscher
Dietrich Stuber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO941142D0 publication Critical patent/NO941142D0/no
Publication of NO941142L publication Critical patent/NO941142L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Humane TNF-muteiner med høyere bindingsaffinitet for human p75-TNF-reseptor enn for human p%%-TNF- reseptor inkluderer muteiner med minst en defekt aminosyre i forhold til vill-type human TNF ved en posisjon som tilsvarer posisjon 33, 65, 67, 75, 87, 143, 145 eller 147 av vill-type aminosyresekvensen. Slike muteiner kan bli brukt til å karakterisere human p75-reseptor og kan, sammen med kjente mute- iner med selektiv bindingsaffinitet for human p55- TNF-reseptor, hjelpe til med å skille mellom TNF- funksjoner mediert via binding til human p75-re- septor og dem mediert via binding til human p55- reseptor.
NO941142A 1993-03-29 1994-03-28 Tumor-nekrosefaktormuteiner NO941142L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93810224 1993-03-29

Publications (2)

Publication Number Publication Date
NO941142D0 NO941142D0 (no) 1994-03-28
NO941142L true NO941142L (no) 1994-09-30

Family

ID=8214942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941142A NO941142L (no) 1993-03-29 1994-03-28 Tumor-nekrosefaktormuteiner

Country Status (14)

Country Link
US (1) US5597899A (no)
EP (1) EP0619372A1 (no)
JP (1) JPH089976A (no)
CN (1) CN1099802A (no)
AU (1) AU5901994A (no)
BR (1) BR9401321A (no)
CA (1) CA2119089A1 (no)
CZ (1) CZ67694A3 (no)
FI (1) FI941459A (no)
HU (1) HUT68218A (no)
IL (1) IL109094A0 (no)
NO (1) NO941142L (no)
NZ (1) NZ260146A (no)
RU (1) RU94009852A (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
SI0975668T1 (sl) 1997-04-15 2007-02-28 Pharmexa As Modificirana molekula TNFalfa, DNA, ki kodira tako modificirano molekulo TNFalfa in cepivo, ki vsebuje tako modificirano molekulo TNFalfa in DNA
CN1062274C (zh) * 1997-10-07 2001-02-21 复旦大学 人肿瘤坏死因子α衍生物及其制备方法
US6354297B1 (en) * 1998-04-16 2002-03-12 The Uniformed Services University Of The Health Sciences Method and device for destroying fat cells by induction of programmed cell death
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
WO2003057856A2 (en) * 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
US7179891B2 (en) * 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
US7642340B2 (en) * 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
CA2542353A1 (en) * 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN106540252B (zh) * 2016-12-07 2020-04-28 四川大学 针对肿瘤坏死因子α的蛋白疫苗及其用途
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
JP7370580B2 (ja) * 2017-04-06 2023-10-30 ウニヴェルズィテート シュトゥットガルト 結合および生物活性を改善した腫瘍壊死因子受容体（ｔｎｆｒ）結合タンパク質複合体
US11957825B2 (en) 2021-06-17 2024-04-16 Immunicom Inc. Modified TNF as a capture ligand

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
GR851626B (no) * 1984-07-05 1985-11-26 Genentech Inc
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
CZ283533B6 (cs) * 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby

Also Published As

Publication number Publication date
BR9401321A (pt) 1994-10-18
AU5901994A (en) 1994-10-06
CA2119089A1 (en) 1994-09-30
FI941459A (fi) 1994-09-30
CN1099802A (zh) 1995-03-08
FI941459A0 (fi) 1994-03-29
HUT68218A (en) 1995-06-28
US5597899A (en) 1997-01-28
HU9400829D0 (en) 1994-06-28
JPH089976A (ja) 1996-01-16
NO941142D0 (no) 1994-03-28
IL109094A0 (en) 1994-06-24
CZ67694A3 (en) 1995-02-15
EP0619372A1 (en) 1994-10-12
NZ260146A (en) 1995-10-26
RU94009852A (ru) 1996-07-20

Similar Documents

Publication Publication Date Title
NO941142L (no) Tumor-nekrosefaktormuteiner
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU5914590A (en) Muteins of human erythropoietin, the preparation thereof and the use thereof
CA2269083A1 (en) Novel fgf homologs
CA2312667A1 (en) Novel cytokine
CA2087958A1 (en) Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
NO893916D0 (no) Fremgangsmaate til prediksjon av vridningsmoment og motstand i avviksborede broenner.
NO894367D0 (no) System og fremgangsmaate for kvantitativ bestemmelse av konsentrasjonene av flere gasser i boreslam.
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
EP2371962A3 (en) Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
CA2108119A1 (en) Glial mitogenic factors, their preparation and use
DK514088A (da) Gasbraender, isaer til anvendelse i et gaskomfurs kogeplader og varmeplader
EP0661970A4 (en) METHOD AND COMPOSITIONS FOR TREATING HIGH PRESSURE, ANGINA AND OTHER DISEASES WITH OPTICALLY PURE (-) AMLODIPINE.
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
NO892737D0 (no) Flammehindrende og roeykhindrende sammensetning.
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
DK6789D0 (da) Fremgangsmaade og apparat til at undertrykke no dannelse i regenerative braendere.
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
AU8164287A (en) 3-(w-(3,5-di-t-butyl-4-hydroxyphenyl)- alkanoyl)pyrroles, their de-oxy analogs, and therapeutic uses thereof
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
HK1024935A1 (en) Protein encoded by the trkb proto-oncogene, used in assay systems for neurothophin activity
HUP0000248A2 (hu) Nagy affinitású interleukin-4 muteinek
EP0815868A4 (en) A CHINESE DRUG COMPOSITION FOR THE TREATMENT OF STOMULIC Ulcers AND THE PRODUCTION THEREOF
NO893892D0 (no) Antimikrobiologisk sammensetning og fremgangsmaate for anvendelse.
NO894008L (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.